Article

Fluoroquinolone helps combat keratitis after lamellar keratectomy

Fort Lauderdale, FL-In a comparison study of three fluoroquinolones, gatifloxacin ophthalmic solution 0.3% (Zymar, Allergan), a new fourth-generation compound, was the most effective agent in the treatment of Mycobacterium chelonae keratitis after lamellar keratectomy in an animal model.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Q&A: Meeting the need for low vision services with wearable tech
June 19th 2025

Q&A: Meeting the need for low vision services with wearable tech

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/Justlight)
June 18th 2025

Ruth Hogg, PhD, on what retinal imaging can tell clinicians about the brain and body

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Ocular Therapeutix to present at Clinical Trials at the Summit 2025
June 18th 2025

Ocular Therapeutix to present at Clinical Trials at the Summit 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada
June 18th 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada

© 2025 MJH Life Sciences

All rights reserved.